Supplementary Figures 1-4 and Supplementary Tables 1-3 from Combination Therapy for KIT-Mutant Mast Cells: Targeting Constitutive NFAT and KIT Activity

Figure S1: HMC1.2 cell line has constitutively actived NFAT2, NFAT2 and NFAT4 species; Figure S2: RT-PCR of transcripts modulated by 24 hour treatment with CSA; Figure S3: CNPIs do not modulate KIT signaling and KIT inhibitors do not affect NFAT localization; Figure S4: Combination therapy does not enhance the effect of KIT inhibitors on KIT or downstream signaling; Table S1: Summary of KIT-mutant mast cell characteristics; Table S2: Summary of antibodies used in immunoblotting experiments; Table S3: qRT-PCR analysis of NFAT expression in KIT-mutant mast cell lines.